Medical News

[ Women Who Suffer Migraine With Aura Have Better Outcomes After Stroke ]

Women Who Suffer Migraine With Aura Have Better Outcomes After Stroke

Women with a history of migraine headache with aura (transient neurological symptoms, mostly visual impairments) are at increased risk of stroke. However, according to new research reported in Circulation: Journal of the American Heart Association stroke events in women with migraine with aura are more likely to have mild or no disability compared to those without migraine. In a new analysis of the Women's Health Study involving 27, 852 women over 13.5 years, researchers found those who have migraine with aura and who experience an ischemic stroke were twice as likely to have no significant disability from stroke. "The message from this study should be reassuring for migraineurs, " said Tobias Kurth, M.D., Sc.D., the study's principal author and associate epidemiologist at Brigham and Women's Hospital in Boston, Mass.

SUMAVEL DosePro Receives Marketing Approval In Germany And The United Kingdom

Aradigm Corporation (OTCBB:ARDM) (the "Company") announced that Zogenix, Inc. ("Zogenix", Nasdaq:ZGNX) and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA). The approvals were received five weeks after receipt of the first European Union ("E.U.") approval for SUMAVEL DosePro in Denmark. According to Zogenix, Germany and the United Kingdom are two of the largest pharmaceutical markets in Europe.

Prescription Acetaminophen Drugs To Have 325 Milligram Limit To Protect Liver

Manufacturers that produce prescription combination products containing acetaminophen are being asked by the FDA to limit the dosage to 325 mg per capsule or tablet to protect liver toxicity. Acetaminophen relives fever and pain and can be found in several OTC (over-the-counter) and prescription medications, such as codeine, Percocet ( oxycodone ), and Vicodin (hydrocodone). The FDA (Food and Drug Administration) has informed manufacturers that all their prescription products containing an acetaminophen combination will need updated labels, warning about potential severe liver injury risk. The FDA, in a communiqu├ today, added that OTC acetaminophen medications are not included in this action. Sandra Kweder, M.D., deputy director of the Office of New Drugs in FDA's Center for Drug Evaluation and Research (CDER), said: "FDA is taking this action to make prescription combination pain medications containing acetaminophen safer for patients to use.

Allergan, MAP Pharmaceuticals 160 Million Inhalable Migraine Treatment Venture

Migraines are a headache. However, a new inhalable treatment is heading to the FDA for full approval before July 2011. Allergan, Inc. and MAP Pharmaceuticals will collaborate promotions of LEVADEX, a self-administered, orally inhaled therapy for migraines in a substantial $160 million deal. Upon FDA approval, Allergan will leverage its existing U.S. sales force currently pushing BOTOX for Chronic Migraine to headache specialists with MAP Pharmaceuticals' field sales force targeting neurologists and pain specialists doubling the reach opportunity. David E.I. Pyott, Allergan's Chairman of the Board and Chief Executive Officer states: "As a company devoted to the advancement of patient care in specialty areas, including neurosciences, we are pleased to partner with MAP Pharmaceuticals to realize the potential of LEVADEX.

The First Animal Model Of A Severe Form Of Migraine Indicates Increased Neuronal Excitability As A Possible Cause

Familial hemiplegic migraine is a rare and severe subtype of migraine with aura, an unusual sensory experience preceding the migraine attack. Researchers from the San Raffaele Scientific Institute in Milan, and CNR Institute of Neuroscience in Pisa, Italy, have developed a mouse model of Familial Hemiplegic Migraine type 2 (FHM2) and used it to investigate the migraine's cause. The study will be published on June 23rd in the open-access journal PLoS Genetics. The researchers developed a knock-in animal model for FHM2 by inserting the W887R mutation of the ATP1A2 gene into the mouse genome. Mutations of this gene have previously been identified in patients as leading to a mutation of the ╬ 2 Na, K-ATPase protein with loss of function. As migraine is a complex phenotype, the research focused on a specific endophenotype that is functionally linked to migraine: cortical spreading depression (CSD).

Fast: [10]

Medical News © Nanda
Designer Damodar